Advancing Breakthroughs, Changing Lives

Bridging the Gap from Discovery to Therapy Through Patient-Centric Investing

Our Human Capital

Our team brings together diverse expertise, unified by our dedication to helping patients

Mary Tolikas, PhD, MBA

SVP, Chief Innovation Officer, Dana-Farber Cancer Institute

Steven Neier, PhD

Principal, Binney Street Capital

Claire Hochleutner, BA

Administrative Support Specialist, Binney Street Capital

Companies Driving Change

Our portfolio companies span a range of healthcare industries and technologies across multiple disease areas

Matchpoint is discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.

Learn More

NextPoint is unlocking the potential of B7-H7 for precision oncology therapeutics.

Learn More

Precede is expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a blood test.

Learn More

Who We Are

Advancing Innovation Through Strategic Investment and Scientific Excellence

Our Mission

Investing with Broad Scope for High Patient Impact

As Dana-Farber Cancer Institute’s venture fund, we invest in innovative companies by leveraging technologies or expertise from the Institute. Although our main focus is oncology therapeutics, we pursue opportunities across a variety of disease areas and sectors to maximize patient impact.

Photo @ Sam Ogden / Dana-Farber

What Makes Us Unique

Grounded in Excellence, Guided by Innovation

Founded in 2021, Binney Street Capital was established to build on Dana-Farber’s legacy of scientific breakthroughs and compassionate care. We leverage the expertise of top tier researchers, clinicians, and business partners to identify and bridge transformative ideas from discovery to clinical validation.

Photo @ Sam Ogden / Dana-Farber

Our Investment Strategy

Breakthrough Science with Transformative Potential

We invest across the innovation life cycle from company creation through early clinical validation. We conduct a rigorous evaluation process and invest in the most promising patient-centric ideas and teams that best balance biological, technical, and translational risks.

Photo @ Sam Ogden / Dana-Farber

Value Add for Portfolio Companies

Building Success, Together

We are dedicated to being a long-term strategic partner at every stage and positioning our portfolio companies for success. In addition to capital, we support our portfolio companies with clinical expertise, insights from cutting edge research, and resources available in Boston and beyond.